Cadila Healthcare
Cadila Healthcare
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return139%
-
Sales Growth18%
-
Return on Equity26 %
Why Super 50
India's fourth largest pharmaceutical company, Cadila proved its mettle in the pharma world when it became the manufacturer of India's first diabetic drug Lipaglyn. The company believes that in order to survive the next decade of competition, it needs to discover and patent its own drugs. Its product pipeline: Three novel biologics, 10 vaccines, and two new chemical entities.
